文献速递肾癌与肾肿瘤

早期肾癌微创与开放手术的肿瘤学结局比较:SEER-Medicare分析

Comparison of Cancer Specific Outcomes following Minimally Invasive and Open Surgical Resection of Early Stage Kidney Cancer from a National Cancer Registry.
PubMed 文献 · J Urol · 2020-01-08

基于SEER-Medicare数据库的回顾性队列研究纳入2004至2013年确诊、66岁及以上、早期非尿路上皮肾癌并在确诊一年内接受手术切除的患者共5,150例,其中3,062例(59.5%)接受微创手术。多变量分析显示微创手术与总生存(HR 0.94,95%CI 0.84-1.06)及疾病特异生存(HR 0.96,95%CI 0.83-1.11)无差异,但微创手术组术后接受全身肿瘤治疗的比例更高(HR 1.31,95%CI 1.09-1.59),二次肾癌手术率无差异。

要点

  • 微创手术与开放手术治疗早期肾癌的总生存和疾病特异生存无显著差异。
  • 微创手术组术后接受全身肿瘤治疗的风险更高(HR 1.31,95%CI 1.09-1.59)。
  • 两种手术方式的二次肾癌手术率无差异。

核心结论

  • 早期肾癌微创手术与开放手术在总生存、疾病特异生存及二次肾癌手术率上无差异,但微创手术组术后全身肿瘤治疗更多,可能提示与微创手术相关的肿瘤学结局差异。

研究设计与样本

  • 回顾性人群队列研究,使用SEER项目与Medicare理赔数据联动。
  • 纳入2004至2013年确诊、年龄至少66岁、早期非尿路上皮肾癌并在确诊一年内接受手术切除的受益人,共5,150例,其中3,062例(59.5%)接受微创手术。
  • 采用多变量回归校正混杂因素。

主要发现

  • 微创手术与总生存无差异(HR 0.94,95%CI 0.84-1.06)。
  • 微创手术与疾病特异生存无差异(HR 0.96,95%CI 0.83-1.11)。
  • 微创手术组接受术后全身肿瘤治疗的比例更高(HR 1.31,95%CI 1.09-1.59)。
  • 手术方式与二次肾癌手术率无差异。

临床怎么用

  • 对于早期非尿路上皮肾癌,微创手术在总生存和疾病特异生存方面不劣于开放手术,可作为可选术式。
  • 术后应关注微创手术患者全身肿瘤治疗需求可能增加,加强随访与肿瘤学监测。

局限性

  • 回顾性观察性研究,可能存在未测量混杂。
  • 仅纳入66岁及以上Medicare受益人,外推至年轻人群需谨慎。
  • 微创手术组全身治疗增加的原因(如分期、病理或复发模式)未在摘要中阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: With anecdotal observations of atypical recurrences following minimally invasive surgery and alongside new concerns following cervical cancer surgery, there is a need to evaluate cancer specific outcomes for minimally invasive kidney cancer surgery using national data. We evaluated cancer specific outcomes following minimally invasive surgery vs open surgery for early stage kidney cancer. MATERIALS AND METHODS: We performed a retrospective population based cohort study using data from the SEER (Surveillance, Epidemiology, and End Results) program linked with Medicare claims that included beneficiaries at least 66 years old diagnosed between 2004 and 2013 with early stage, nonurothelial kidney cancer who underwent surgical resection within a year of diagnosis. We compared overall survival, disease specific survival, rate of second kidney cancer surgery and rate of postoperative systemic cancer therapy based on whether surgery was minimally invasive surgery or an open resection. Multivariable regression was used to account for confounders. RESULTS: A total of 5,150 patients were included in analysis and 3,062 (59.5%) underwent minimally invasive surgery. On multivariable analysis minimally invasive surgery was not associated with differences in overall survival (HR 0.94, 95% CI 0.84-1.06) or disease specific survival (HR 0.96, 95% CI 0.83-1.11). Patients treated with minimally invasive surgery were more likely to receive systemic cancer therapy (HR 1.31, 95% CI 1.09-1.59). No difference in the rate of second surgery associated with surgical approach was observed. CONCLUSIONS: Use of minimally invasive surgery for early stage kidney cancer was not associated with differences in overall or disease specific survival, or the rate of second kidney cancer surgery. Patients treated with minimally invasive surgery received more postoperative systemic therapy, which could represent a disparate cancer specific outcome associated with minimally invasive surgery.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Auffenberg GB, Curry M, Gennarelli R, et al. Comparison of Cancer Specific Outcomes following Minimally Invasive and Open Surgical Resection of Early Stage Kidney Cancer from a National Cancer Registry. J Urol. 2020. PMID: 31913076. doi:10.1097/JU.0000000000000741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。